TY - JOUR
T1 - Development of live attenuated influenza vaccines against pandemic influenza strains
AU - Coelingh, Kathleen L.
AU - Luke, Catherine J.
AU - Jin, Hong
AU - Talaat, Kawsar R.
N1 - Funding Information:
KC is an employee of AstraZeneca, HJ is an employee of MedImmune; both may hold stock or stock options in AstraZeneca, the parent company of MedImmune. CL is a member of the Executive Committee for a Cooperative Research and Development Agreement between NIH and MedI-mmune. KT has no competing interests to declare. The influenza pandemic vaccine program is conducted as part of a Cooperative Research and Development Agreement between MedImmune and the Laboratory of Infectious Diseases, NIAID. This research was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. The 2009 H1N1pdm LAIV studies were funded in whole or in part with Federal funds from the HHS Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract HHS0100200900021. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilized in the production of this manuscript. Editorial assistance was provided by DeRocco SE and Fincke JE of Complete Healthcare Communications, Inc. (Chadds Ford, PA) and was funded by MedImmune.
PY - 2014/7
Y1 - 2014/7
N2 - Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.
AB - Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.
KW - LAIV
KW - intranasal influenza vaccine
KW - pandemic influenza vaccine
UR - http://www.scopus.com/inward/record.url?scp=84902332892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902332892&partnerID=8YFLogxK
U2 - 10.1586/14760584.2014.922417
DO - 10.1586/14760584.2014.922417
M3 - Review article
C2 - 24867587
AN - SCOPUS:84902332892
VL - 13
SP - 855
EP - 871
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
SN - 1476-0584
IS - 7
ER -